elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Cetuximab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Cetuximab
RIS
0.001
(Research Intensity Score)
Papers
239
Top papers
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
2019 · 3404 citations
Comprehensive review of targeted therapy for colorectal cancer
2020 · 1699 citations
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
2023 · 126 citations
Advances in targeted therapy for esophageal cancer
2020 · 555 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · 1703 citations
Newest papers
Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer
2026 · 10 citations
Nanomedicine as an opportunity for equity achievements through cost-reduction in public healthcare for head and neck cancer treatment in Brazil
2026 · 4 citations
Real-World Outcomes of First-Line Cetuximab and Platinum-Based Chemotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter Observational Study and Literature Review
2026 · 1 citations
Impact of combined positive score in cetuximab plus chemotherapy in recurrent/metastatic head and neck cancer: A real-world study
2026
A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor
2026
A sample from the 100 top papers behind Cetuximab.
Create a free account to browse them all →
Cetuximab's history
Research intensity over time
Explore Cetuximab's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Cetuximab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link